Evotec stock at EUR 3.18, up 1.27% pre-market
Published on 11/10/2026 at 08:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSProfitability improves as outlook holds
- Evotec's third-quarter adjusted EBITDA loss narrowed sharply from the prior-year period.
- Management reaffirmed its full-year 2026 revenue and adjusted EBITDA guidance.
- The Horizon program had delivered more than 20 percent of its targeted annual savings by the end of September.
Evotec stock traded at EUR 3.18 on Lang & Schwarz at 07:59 CET on Tuesday, November 10, 2026, 1.27 percent above the Xetra close of Monday, November 9, at EUR 3.14.
The biotechnology company is entering the session after its third-quarter and nine-month update kept the full-year outlook unchanged. Evotec expects 2026 Group revenue of EUR 570 million to EUR 610 million and adjusted Group EBITDA of negative EUR 105 million to negative EUR 70 million.
Horizon savings support quarterly recovery
According to PR Newswire, third-quarter Group revenue reached EUR 164.9 million, broadly stable year on year, while adjusted Group EBITDA improved to a loss of EUR 1.6 million from a loss of EUR 15.0 million in the prior-year quarter. Nine-month revenue fell 13.1 percent to EUR 465.0 million, and adjusted Group EBITDA was a loss of EUR 44.3 million.
Evotec said its Horizon transformation was ahead of plan. More than 20 percent of the EUR 75 million annual run-rate savings target had been delivered by the end of September. The company also said that three of four planned site closures were expected to be completed by year-end, with the fourth scheduled for the first quarter of 2027.
The company presented a 2030 framework targeting around EUR 1 billion in Group revenue and an adjusted EBITDA margin above 20 percent by year-end 2030. Just - Evotec Biologics is expected to account for about 40 percent of that revenue, alongside Discovery and Preclinical Development services and strategic partnerships.
Market conditions remain relevant for German biotechnology shares; investors can follow the DAX for the broader domestic benchmark.
More news and analysis are available on Evotec stock.
